• Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Insights & Innovations Blog

Find the latest updates, spotlights, and news from CCG.

  • TRACERx: Trailblazing Longitudinal Cancer Genomics
    June 1, 2017, by Jean C. Zenklusen, M.S., Ph.D.

    The Cancer Genome Atlas (TCGA) has been analyzed in more than one thousand scientific publications and enabled countless discoveries, but mostly using cross-sectional studies. To study in depth how cancer evolves and progresses, NCI's Center for Cancer Genomics (CCG) is supporting the innovative, longitudinal study Tracking Non-Small-Cell Lung Cancer Evolution through Therapy (TRACERx).

    Continue Reading >

  • ROS1+ Cancer Patients Partner to Increase Research
    May 23, 2017, by Janet Freeman-Daily, MS, Eng

    ROS1ders, a group of lung cancer patients who share a rare genetic abnormality involving the ROS1 gene, united to support each other and promote research. They formed the Global ROS1 Initiative, a collaboration between foundations, academic researchers, and industry that aims to improve outcomes for future patients.

    Continue Reading >

  • Researchers Design a Precise Library for CRISPR-Mediated Genetic Screens
    April 6, 2017, by Amy E. Blum, M.A.

    Researchers in the Cancer Target Discovery and Development Network used machine learning to create improved CRISPR libraries for genomic studies. Their new libraries of single guide RNAs can be used to alter gene expression with greater sensitivity and specificity.

    Continue Reading >

  • Democratizing Access to CCG Data: Cancer Genomics Cloud Pilots
    March 7, 2017, by Izumi Hinkson, Ph.D.

    Big data is essential to cancer research. Yet as we collect more cancer data, we limit the number of researchers who can participate. By enabling access to NCI data and computational resources in the cloud, the cloud pilots contribute to a cancer data ecosystem that enables diverse researchers to advance precision oncology.

    Continue Reading >

  • Functional Genomics Study Finds Druggable Target in KRAS-mutant Lung Cancer
    February 2, 2017, by Amy E. Blum, M.A.

    A new study by the Cancer Target Discovery and Development Network identified XPO1 as a vulnerability specific to KRAS-mutant lung cancers that responds to available drugs. Paired with genomics-based patient selection, this finding could improve lung cancer care.

    Continue Reading >

Featured Posts